ABK Biomedical

ABK Biomedical is a company based in Halifax, Nova Scotia, Canada, that focuses on developing novel Y90 radioembolization treatment options for patients with hypervascular liver tumors. The company's lead product, Eye90 Microspheres, has been granted breakthrough device designation by the U.S. Food and Drug Administration, and the company is conducting a multi-center pivotal study of the device.